Healthcare Global Enterprises Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Healthcare Global Enterprises Ltd trades at ₹656, in a confirmed uptrend and 5 weeks into that stage. That is +6.7% against its own 200-day average. It sits at 56% of a 52-week range of ₹532 to ₹755. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).

Today the stock is in a confirmed uptrend — week 5 of stage 2, confirmed. At ₹656 it trades +6.7% versus its 200-day average and sits at 56% of its 52-week range (₹532–₹755).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +277% while the NIFTY 500 moved +266% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 88th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Healthcare Global Enterprises Ltd trades at 346.0× P/E, at the pricey end of its own range (88th percentile). Its long-run median P/E is 157.5×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 346.0× is at the pricey end of its own range (88th percentile), against a long-run median of 157.5× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved −69.4% against a +14.4% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 10y, of the +13.3%/yr price move, ~+13.6%/yr came from earnings growth and ~−0.3 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 95% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Healthcare Global Enterprises Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 8.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

35.0/100 — rank 18 of 19 in Hospitals · 66% evidence confidence

Healthcare Global Enterprises Ltd scores 35.0 out of 100 against the 19 companies it is compared with in Hospitals, ranking 18. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 13.1 + 6.5 + 8.5 + 6.9 = 35. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Healthcare Global Enterprises Ltd reported ₹652 Cr of revenue in the Mar 26 quarter, +11.5% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 15.9% a year. The last full year, FY26, came in at ₹2,545 Cr. The last four reported quarters add to ₹2,545 Cr.

Healthcare Global Enterprises Ltd reported ₹652 Cr of revenue in the Mar 26 quarter, +11.5% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 15.9% a year. The last full year, FY26, came in at ₹2,545 Cr. The last four reported quarters add to ₹2,545 Cr.

FY26 revenue came in at ₹2,545 Cr (+14.7% on the year), capping 10 years at 15.9% compound. The latest quarter (Mar 26) printed ₹652 Cr, +11.5% year on year — the 10th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +14.6% growth against the decade's 15.9% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +14.5% over the last 4 quarters against +15.4%/yr over the last 8 — stabilising; TTM profit −53.3% vs −25.7%/yr — rolling over.

→ Revenue grew — did margins hold as it scaled? Next: 19.2% this quarter (+1.1 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Healthcare Global Enterprises Ltd's operating margin is 19.2% in the Mar 26 quarter, +1.1 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 9.0% to 18.0%. The current quarter is running above every full year in that window.

Healthcare Global Enterprises Ltd's operating margin is 19.2% in the Mar 26 quarter, +1.1 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 9.0% to 18.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 19.2%, +1.1 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0%–18.0%, and FY26's 18.0% is the top of that band — a record year.

Why the margin moved: operating margin went +1.1 pp year on year while gross margin went −0.8 pp — the gain came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

→ Margins held — did that reach the bottom line? Next: profit −40.3% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Healthcare Global Enterprises Ltd earned ₹4.0 Cr of net profit in the Mar 26 quarter, −40.3% year on year. Full-year FY26 profit was ₹23.0 Cr. The 10-year compound rate is 27.7%. That is 0.6% of the quarter's revenue. The same quarter a year earlier earned ₹6.8 Cr. 1 of the last 12 reported quarters were loss-making.

Healthcare Global Enterprises Ltd earned ₹4.0 Cr of net profit in the Mar 26 quarter, −40.3% year on year. Full-year FY26 profit was ₹23.0 Cr. The 10-year compound rate is 27.7%. That is 0.6% of the quarter's revenue. The same quarter a year earlier earned ₹6.8 Cr. 1 of the last 12 reported quarters were loss-making.

Mar 26 profit was ₹4.0 Cr, −40.3% year on year. On the full year, FY26 printed ₹23.0 Cr (−53.1%), and the 10-year compound rate is 27.7%.

🚨 Why profit moved: revenue contributed +11.5% and the margin +1.1 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit −74.6% vs revenue +14.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

→ Profit rose — but did the cash follow? Next: 840% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 840% of Healthcare Global Enterprises Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹347 Cr of operating cash against ₹23.0 Cr of profit. After ₹258 Cr of capital spending, ₹89.0 Cr was left as free cash.

FY26: operating cash of ₹347 Cr against reported profit of ₹23.0 Cr, leaving free cash of ₹89.0 Cr after ₹258 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 840% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 840%: the cash cycle stretched 28 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 2.4× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹1,539 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Healthcare Global Enterprises Ltd's cash conversion cycle runs −93 days in FY26, up from −121 days in FY21. Capital spending ran ₹1,539 Cr over the last 3 years. At FY26 sales of ₹2,545 Cr each day of that cycle holds about ₹7.0 Cr, so roughly ₹−648 Cr sits inside the business at any moment.

FY26: debtors at 60 days, inventory at 32 days — roughly 1.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −93 days, looser than FY21's −121.

The full loop: cash goes out to suppliers and production on day 0; stock waits 32 days to sell; customers pay about 60 days after that; and suppliers themselves are paid at 185 days — netting out to the −93-day cycle.

In money terms: at FY26 sales of ₹2,545 Cr, each day of the cycle holds about ₹7.0 Cr — so the −93-day loop keeps roughly ₹−648 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹1,539 Cr over the last 3 fiscal years against ₹629 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹19.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 8%.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Healthcare Global Enterprises Ltd earns a ROCE of 8% in FY26. That is up from a trough of −1% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 0.9% net margin on 0.65× asset turns.

FY26 ROCE is 8%, recovered from a FY21 trough of −1% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 0.9% net margin × 0.65× asset turns × 2.95× balance-sheet leverage ≈ 1.7% on equity. Margin does its share; leverage is a meaningful part of the equation.

The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 95% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 1.30.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Healthcare Global Enterprises Ltd carries ₹1,735 Cr of borrowings against ₹1,332 Cr of equity in FY26, a debt-to-equity of 1.30. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹977 Cr to ₹1,735 Cr. Capital spending ran ₹1,539 Cr across the last 3 of those years.

FY26: borrowings of ₹1,735 Cr against equity of ₹1,332 Cr — a debt-to-equity of 1.30. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹977 Cr to ₹1,735 Cr while capital spending ran ₹1,539 Cr in just the last 3 — part of the build-out is riding on borrowed money.

The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 95% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 8.3 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 8.3 points of Healthcare Global Enterprises Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 19.2% of the company. Promoters moved −7.1 points over the same window, to 64.2%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +8.3 points over 8 quarters to 19.2%; Promoters: −7.1 points over 8 quarters to 64.2%; Foreign institutions: −1.2 points over 8 quarters to 2.7%.

Why the register moved: domestic institutions drove it (+8.3 points), absorbed on the other side by promoters (−7.1 points) — steady accumulation by institutions reading the same numbers this page reads.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Healthcare Global Enterprises Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions